{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250"},{"comment":"The MTD for oprozomib GR in combination with pomalidomide and dexamethasone was not determined due to too few DLTs.","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"The MTD was the dose with the highest posterior probability of having a DLT rate within the target toxicity interval (15% to 25%), while the posterior probability of excessive/unacceptable toxicity (\\>25% to 100%) is \\<40%.\n\nDLTs were graded using CTCAE version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia \\> 24 hours); Grade 3 nausea, vomiting and diarrhea \\< 3 days; Grade 3 fatigue \\< 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count \\< 0.5 x 10\\^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.","groups":[{"description":"Participants who received oprozomib IR in a 2/7 schedule in combination with pomalidomide and dexamethasone in Part 2. Doses of oprozomib IR administered were 150 mg/day (N=4), 200 mg/day (N=8), 225 mg/day (N=10), and 250 mg/day (N=8).","id":"OG000","title":"All Doses Oprozomib IR + Pomalidomide + Dexamethasone"},{"description":"Participants who received oprozomib GR in a 2/7 schedule in combination with pomalidomide and dexamethasone in Part 2. Doses of oprozomib GR administered were 150 mg/day (N=4), and 200 mg/day (N=5).","id":"OG001","title":"All Doses Oprozomib GR + Pomalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"DLT-evaluable participants in Part 2 who received the following during the 28-day DLT window: all planned doses of oprozomib, a minimum of 17 of 21 planned doses of pomalidomide, and a minimum of 6 of 8 planned doses of dexamethasone.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28 of cycle 1, where each cycle was 28 days","title":"Maximum Tolerated Dose (MTD) of Each Formulation of Oprozomib in Combination With Pomolidomide and Dexamethasone","type":"PRIMARY","unitOfMeasure":"mg/day"}